More than 80% of SLE patients experience some type of neurologic manifestation during their disease course. The challenge for rheumatologists and other clinicians lies in appropriately diagnosing any cognitive dysfunctions that accompany lupus and better understanding the causes and risk factors of those dysfunctions. “Cognitive Function in SLE” was the focus of a talk at the 2011 ACR/ARHP Annual Scientific Meeting in November.
A Window into Health Disparities
Systemic lupus erythematosus offers a touchstone for the U.S. healthcare system–and how we care for vulnerable patients
When Steroids Cause Psychosis
Medical management of this side effect is complicated in rheumatology patients.
TNF Blockade for SLE
Reckless approach versus missed opportunity?
Mitigate Risk and Increase Success of Lupus Clinical Trials
Design strategies from a Lupus Research Institute conference
Drug Updates
Information on New Approvals and Medication Safety
Is B a Key to Autoimmune Therapy?: B Cell-Targeted Therapies in Autoimmune Disease
A perspective on B cell–targeted therapies in autoimmune disease
Systemic Lupus Erythematosus
Systemic lupus erythematosus, often called SLE or lupus, is a chronic inflammatory disease that can affect the skin, joints, kidneys, lungs, nervous system, and other organs of the body. It is sometimes labeled the “great imitator” because its wide variety of symptoms can often be confused with other disorders. Usually, patients with SLE experience skin rashes and arthritis as well as fatigue and fever, and the disease can be fatal. However, improvements in therapy have significantly increased these patients’ quality of life and their life expectancy.
The Brain in Lupus
The Mary Kirkland Center lupus conference offers insight into cognitive aspects of SLE
Safety First
Phase 1 clinical trials present recruitment challenges for rheumatology researchers